REG - Cambridge Cognition - Notice of Results and Investor Presentation

Cambridge Cognition HoldingsAnnouncement

24/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX9241Fa&default-theme=true

RNS Number : 9241F  Cambridge Cognition Holdings PLC  24 April 2025

24 April 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Notice of Results and Investor Presentation via Investor Meet Company

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital products to advance clinical research and patient treatment, will
announce its Preliminary Results for the year ended 31 December 2024 on
Thursday 1(st) May 2025.

Rob Baker, Joint Managing Director and Chief Operating Officer, and Ronald
Openshaw, (acting Chief Financial Officer), will provide a live presentation
via Investor Meet Company at 11:00 BST on Thursday 1(st) May 2025.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
30 April 2025, 9:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Cambridge Cognitions Holdings plc via:

https://www.investormeetcompany.com/cambridge-cognition-holdings-plc/register-investor
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fcambridge-cognition-holdings-plc%2Fregister-investor&data=05%7C02%7Chdreyfus%40hudsonsandler.com%7C2037be1c5fc64cc393f308dd7ce7e246%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638804057622952374%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=8XcJzF1kmnjx7JZBKGm1pwteU4h9jb%2FD9w4ozkWCfkY%3D&reserved=0)

Investors who already follow Cambridge Cognitions Holdings plc on the Investor
Meet Company platform will automatically be invited.

- Ends -

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Jackson Redley                  cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products to advance brain health research and treatment.

The Company offers four core products:

· CANTAB® assessments-providing scientifically validated, highly sensitive,
precise, and objective measures of cognitive function correlated to neural
networks;

· a flexible and proven eCOA platform with an extensive library of
instruments, enabling efficient study setup and scalable data capture;

· rater training services that standardise assessment delivery and scoring
across clinical trials; and,

· quality assurance tools that ensure data integrity by automatically
detecting deviations in administration and scoring, saving time and money.

These products collectively improve clinical trial outcomes, enable early
patient identification, and enhance global efficiency in healthcare and
pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORPKNBPPBKDOQB